4D Molecular Therapeutics, Inc. (FDMT)

14.67 -1.61% (-0.24)

Over 1Y: +137.4%

2026-08-28
Style
Area Line Line with markers Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

10 15
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '21 — Revenue: 1.4M Q3 '21 — Operating Cash Flow: -15.7M Q3 '21 — Net Income: -22.2M Q4 '21 — Revenue: 92K Q4 '21 — Operating Cash Flow: -21.8M Q4 '21 — Net Income: -25.1M Q1 '22 — Revenue: 1.2M Q1 '22 — Operating Cash Flow: -23.6M Q1 '22 — Net Income: -26.3M Q2 '22 — Revenue: 162K Q2 '22 — Operating Cash Flow: -19.9M Q2 '22 — Net Income: -28.1M Q3 '22 — Revenue: 500K Q3 '22 — Operating Cash Flow: -21M Q3 '22 — Net Income: -25.7M Q4 '22 — Revenue: 1.2M Q4 '22 — Operating Cash Flow: -22.2M Q4 '22 — Net Income: -27.4M Q1 '23 — Revenue: 298K Q1 '23 — Operating Cash Flow: -27.9M Q1 '23 — Net Income: -28.7M Q2 '23 — Revenue: 239K Q2 '23 — Operating Cash Flow: -22.1M Q2 '23 — Net Income: -29.6M Q3 '23 — Revenue: 20.2M Q3 '23 — Operating Cash Flow: -1.2M Q3 '23 — Net Income: -10.3M Q4 '23 — Revenue: -19K Q4 '23 — Operating Cash Flow: -24.6M Q4 '23 — Net Income: -32.3M Q1 '24 — Revenue: 28K Q1 '24 — Operating Cash Flow: -29.1M Q1 '24 — Net Income: -32.4M Q2 '24 — Revenue: 5K Q2 '24 — Operating Cash Flow: -30.2M Q2 '24 — Net Income: -35M Q3 '24 — Revenue: 3K Q3 '24 — Operating Cash Flow: -29.4M Q3 '24 — Net Income: -43.8M Q4 '24 — Revenue: 1K Q4 '24 — Operating Cash Flow: -45.9M Q4 '24 — Net Income: -49.7M Q1 '25 — Revenue: 14K Q1 '25 — Operating Cash Flow: -47.8M Q1 '25 — Net Income: -48M Q2 '25 — Revenue: 15K Q2 '25 — Operating Cash Flow: -43.4M Q2 '25 — Net Income: -54.7M Q3 '25 — Revenue: 90K Q3 '25 — Operating Cash Flow: -46.5M Q3 '25 — Net Income: -56.9M Q4 '25 — Revenue: 85.1M Q4 '25 — Operating Cash Flow: 28.6M Q4 '25 — Net Income: 19.4M Q1 '26 — Revenue: 3M Q1 '26 — Operating Cash Flow: -68.1M Q1 '26 — Net Income: -68.8M Q2 '26 — Revenue: 3.8M Q2 '26 — Operating Cash Flow: -70M Q2 '26 — Net Income: -72.9M -70M -35M 0 35M 70M 105M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.8
SBC / sales 22.2%
OE margin -192.4%
Oper. margin -214.2%
ROIC -236.3%
Accruals -4.7%
EBITDA margin -208.8%
FCF margin -170.2%
OCF margin -169.6%
Profit margin -194.7%
ROA -36.4%
ROCE -44.3%
ROE -44.0%
Gross margin —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales 0.0039×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.2
ND/EBITDA —
Cash runway 2.2 yr
Cash / Debt 18.4×
Debt / Eq 0.048×
Debt payback 0.0 yr
Quick ratio 8.0×
F-score 3.9 pts
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

9.1
Sales/sh Y/Y +259513.1%
Sales CAGR 4Y +47.4%
Sales Q/Q +25106.7%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.